On October 18, 2023 Traverse Biotech, Inc reported that the National Cancer Institute (NCI) of the National Institutes of Health has awarded them a Small Business Innovation Research (SBIR) Phase 1 Grant to fund the development of a unique bispecific antibody approach for treating Non-small Cell Lung Cancer (NSCLC), the most prevalent type of lung cancer in the United States (Press release, Traverse Biotech, OCT 18, 2023, View Source [SID1234636125]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Brandy Houser, Co-founder and CEO of Traverse Biotech, stated "We are excited about the NCI’s interest and support of this technology. We believe that T cell-engager bispecific antibodies could potentially serve as a valuable treatment option for NSCLC and other solid tumors expressing our target tumor antigen."

"This NCI funding will help us to validate our novel tumor antigen as a unique target and move our bispecific antibody forward in the field of cancer immunotherapy," added Dr. Jean-Loup Romet-Lemonne, Traverse Biotech’s Co-founder and Principal Investigator for this grant.

Research is supported by the NCI at the National Institutes of Health under award number R43CA285040-01. Authors are entirely responsible for the content of this press release and therefore the content does not necessarily represent the views of the NIH.